Skip to content

Employing eSBI in HIV Testing for At-risk Youth

Employing eSBI in a Community-based HIV Testing Environment for At-risk Youth

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02703116
Enrollment
464
Registered
2016-03-09
Start date
2016-08-31
Completion date
2020-10-31
Last updated
2021-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV, Substance Use

Keywords

HIV, Substance Use

Brief summary

The purpose of this study is to assess the feasibility, acceptability and test the initial efficacy of eSBI, (electronic screening and brief intervention for alcohol use) coupled with STTR (Seek, Test, Treat, and Retain) in comparison to STTR only among YMSM (young men who have sex with men) and YTW (young transgender women) on frequency of substance use and engagement within the HIV (human immunodeficiency virus) and PrEP (pre-exposure prophylaxis) care continuum.

Detailed description

The purpose of this study is to assess the feasibility, acceptability and test the initial efficacy of eSBI, (electronic screening and brief intervention for alcohol use) coupled with STTR (Seek, Test, Treat, and Retain) in comparison to STTR only among YMSM (young men who have sex with men) and YTW (young transgender women) on frequency of substance use and engagement within the HIV and PrEP (pre-exposure prophylaxis) care continuum. We will do this with the following aims: Aim 1: Assess the feasibility, acceptability and initial efficacy of electronic Screening & Brief Intervention + Seek, Test, Treat and Retain (eSBI+ STTR) compared to STTR-only to reduce alcohol and other substance use among 450 YMSM and YTW in Chicago, ages 16-25, at 1, 3, 6, and 12 months post-intervention. Aim 2: To explore the initial efficacy of eSBI+STTR in comparison to STTR-only on secondary exploratory outcomes within the HIV and PrEP care continuum among YMSM and YTW. Aim 3: Determine the degree to which sub-groups of youth are differentially impacted by eSBI+STTR based on socio-demographic characteristics and co-morbid mental health problems to inform future targeting and/or tailoring of the intervention.

Interventions

BEHAVIORALAlcohol Use BI

Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.

BEHAVIORALNutrition Intervention

Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Ann & Robert H Lurie Children's Hospital of Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* aged 16 to 25 years * seeking testing for HIV infection * HIV-negative or HIV status unknown (per self-report) * Male who has had sex with men OR transgender woman who has had sex with men (i.e., born male, identify as female/transgender, and at any point in the gender transition process) * English-speaking.

Exclusion criteria

* volunteer seems distraught or emotionally unstable (i.e. suicidal, manic, exhibiting violent behavior) * volunteer seems intoxicated or under the influence of psychoactive agents

Design outcomes

Primary

MeasureTime frameDescription
Change in Frequency of Alcohol Use1, 3, 6 and 12 months post-interventionSelf-reported frequency of alcohol use in the previous 1 and 12 months assessed via computer-assisted self-interviewing.

Secondary

MeasureTime frameDescription
PrEP and HIV-related Care Engagement1, 3, 6 and 12 months post-interventionPrEP and HIV-related medical care engagement (completed clinical visits) will be abstracted from medical records.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026